证券代码：002612 证券简称：朗姿股份 公告编号：2025-035 朗姿股份有限公司 关于接受关联方担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 注册资本：442,445,375 元人民币 成立日期：2006 年 11 月 09 日 注册地址：北京市顺义区马坡镇白马路 63 号 经营范围：一般项目：服装服饰零售；服饰研发；服饰制造；服装服饰批发； 服装、服饰检验、整理服务；服装辅料销售；互联网销售（除销售需要许可的商 品）；服装辅料制造；服装制造；针纺织品及原料销售；鞋帽批发；鞋帽零售； 母婴用品销售；劳动保护用品生产；劳动保护用品销售；珠宝首饰制造；珠宝首 饰批发；珠宝首饰零售；会议及展览服务；企业管理；企业管理咨询；信息咨询 服务（不含许可类信息咨询服务）；信息技术咨询服务；技术服务、技术开发、 技术咨询、技术交流、技术转让、技术推广；五金产品制造；五金产品批发；五 金产品研发；五金产品零售；玩具制造；玩具销售；皮革制品制造；皮革制品销 售；皮革、毛皮及其制品加工专用设备制造；皮革、毛皮及其制品加工专用设备 销售；箱包制造；箱包销售；日用 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2025-033 朗姿股份 法定代表人：申东日 注册资本：442,445,375 元人民币 成立日期：2006 年 11 月 09 日 注册地址：北京市顺义区马坡镇白马路 63 号 朗姿股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于接受关联方担保的情况概述 为满足日常经营和业务发展资金需要，朗姿股份有限公司（以下简称"公司" 或"朗姿股份"）向广发银行股份有限公司北京光华路支行（以下简称"广发银行"） 申请最高授信额度人民币 6,000 万元，公司控股股东、实际控制人申东日先生及 其配偶翁洁女士为公司提供保证担保。 公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司提供本次保 证担保，该担保不向公司收取任何担保费用，也不需要公司提供反担保。 二、被担保人基本情况 经营范围：一般项目：服装服饰零售；服饰研发；服饰制造；服装服饰批发； 服装、服饰检验、整理服务；服装辅料销售；互联网销售（除销售需要许可的商 品）；服装辅料制造；服装制造；针纺织品及原料销售；鞋帽批发；鞋帽零售； 母婴 ...

关于全资子公司为公司提供担保并接受关联方担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002612 证券简称：朗姿股份 公告编号：2025-034 朗姿股份有限公司 特别提示： 1、朗姿股份有限公司（以下简称"朗姿股份"或"公司"）第五届董事会 第二十九次会议和 2024 年度股东大会分别审议通过了《关于 2025 年度对外担保 额度的议案》，同意 2025 年度公司及其控股子公司的对外担保总额不超过 30.50 亿元（以下除非特别注明，所称"元"均指"人民币元"），其中对资产负债率 未超过 70%的控股子公司担保额度为 24.00 亿元，对资产负债率超过 70%的控股 子公司担保额度为 6.50 亿元。该担保额度的有效期自公司 2024 年度股东大会审 议批准本议案之日起至 2025 年度股东大会召开之日止。截至本公告披露日，公 司及控股子公司对外担保总余额为 123,865 万元，占公司 2024 年度经审计净资 产的 44.44%；其中，实际被担保方四川米兰柏羽医学美容医院有限公司、北京 莱茵服装有限公司资产负债率超过 70%，公 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2025-033 二、被担保人基本情况 朗姿股份 法定代表人：申东日 朗姿股份有限公司 关于接受关联方担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于接受关联方担保的情况概述 为满足日常经营和业务发展资金需要，朗姿股份有限公司（以下简称"公司" 或"朗姿股份"）向广发银行股份有限公司北京光华路支行（以下简称"广发银行"） 申请最高授信额度人民币 6,000 万元，公司控股股东、实际控制人申东日先生及 其配偶翁洁女士为公司提供保证担保。 公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司提供本次保 证担保，该担保不向公司收取任何担保费用，也不需要公司提供反担保。 股权结构：详见公司披露于巨潮资讯网（www.cninfo.com.cn）的《2024 年年 度报告》"第七节、股份变动及股东情况"。 主要财务数据： | 单位：万元 | | --- | | 科目 | 2024年12月31日（经审计） | 2025年3月31日（未经审 | | | --- | --- | --- | --- | ...

Group 1 - The core point of the news is that Langzi Co., Ltd. plans to reduce its stake in Ruoyuchen by up to 3% within 15 trading days, following a previous cash-out of 217 million yuan, indicating a strategic move to support its expanding medical beauty business [1][4][6] - Ruoyuchen's stock price has surged by 534% over the past year, with a year-to-date increase of over 150%, prompting Langzi's decision to sell at a high point [1][4] - Langzi's investment in Ruoyuchen has yielded over 8 times returns, marking it as one of its most successful financial investments in recent years [4][6] Group 2 - Ruoyuchen, founded in 2011 and listed in September 2020, has seen a significant shift in its business structure, with traditional e-commerce operations declining while its own brand business is on the rise [4][5] - The revenue from Ruoyuchen's self-owned brands has grown from 73.97 million yuan in 2021 to approximately 263 million yuan in 2023, accounting for nearly 19.27% of total revenue [5] - The overall gross margin for Ruoyuchen reached 44.57% in 2024, with self-owned brands achieving a gross margin of 67%, significantly higher than its other business segments [5] Group 3 - Langzi's medical beauty business has become its main revenue driver, contributing 2.784 billion yuan in 2024, which is 48.92% of total revenue, surpassing its fashion women's wear segment [9][10] - Despite the growth, the gross margin for the medical beauty segment is only 54.42%, which is lower than the 63.45% margin for the women's wear segment [9][10] - Langzi's short-term borrowings have surged by 92.11% year-on-year, indicating increasing financial pressure as it expands its medical beauty operations [9][14] Group 4 - Langzi has faced compliance issues within its medical beauty operations, with several institutions under its umbrella encountering penalties for various violations [13] - The company is actively seeking funding to support its medical beauty expansion, which may include repaying upcoming debts and acquiring regional medical beauty institutions [13][14] - The medical beauty market in China has significant growth potential, with a penetration rate of only 3%-5%, compared to 20% in South Korea, but faces challenges from competitors and macroeconomic fluctuations [13][14]

Market Performance - The C2M concept declined by 3.30%, ranking among the top declines in the concept sector as of the market close on June 13 [1] - Within the C2M sector, notable declines were observed in companies such as Nanshan Zhishang, Huafang Co., and Mengjie Co., while Mingpai Jewelry, Nangang Co., and Oppein Home saw slight increases of 1.50%, 0.73%, and 0.17% respectively [1] Capital Flow - The C2M concept experienced a net outflow of 7.92 billion yuan in principal funds today, with 35 stocks seeing net outflows, and 10 stocks exceeding 30 million yuan in outflows [2] - The stock with the highest net outflow was Hand Information, with a net outflow of 1.88 billion yuan, followed by Qingdao Jinkong, Huafang Co., and Langzi Co. with net outflows of 795.96 million yuan, 711.62 million yuan, and 446.39 million yuan respectively [2] Top Gainers and Losers - The top gainers in the C2M sector included Mingpai Jewelry, Meike Home, and Baoxiniu, with net inflows of 1.85 million yuan, 1.58 million yuan, and 1.56 million yuan respectively [2] - The C2M concept outflow leaderboard featured stocks like Hand Information (-5.12%), Qingdao Jinkong (-4.96%), and Huafang Co. (-7.11%) [3]

Core Viewpoint - The botulinum toxin industry in China is experiencing rapid growth, with the market size projected to increase from 1.9 billion yuan in 2017 to 9.9 billion yuan by 2024, reflecting a compound annual growth rate (CAGR) of 26.6% [1][13]. Industry Overview - Botulinum toxin, originally used for treating muscle spasms, has become a popular choice in medical aesthetics due to its minimal invasiveness and quick recovery time [3][13]. - The application range of botulinum toxin is expanding beyond traditional uses like wrinkle reduction and facial slimming to include treatments for conditions such as migraines and muscle tension disorders [1][13]. Market Dynamics - The medical aesthetics market in China is projected to reach 288 billion yuan by 2024, with a year-on-year increase of 8.03%, indicating a growing consumer demand for beauty enhancement services [11][13]. - The market is characterized by a "six-way split" among leading products, with brands like Botox, Hengli, and Letyb gaining significant market shares [15][17]. Competitive Landscape - The botulinum toxin market is competitive, with established companies like Fosun Pharma, Haohai Biological Technology, and Lanzhou Biological Products Research Institute leading the industry [17][18]. - New entrants are emerging, leveraging innovative technologies and marketing strategies to capture market share [17]. Development Trends 1. **Increasing Industry Penetration** - As living standards rise, the penetration rate of medical aesthetics is expected to increase, particularly in lower-tier cities and rural areas, driven by a younger consumer base [23]. 2. **Enhanced Regulatory Oversight** - The government is intensifying regulations on botulinum toxin production and distribution to ensure safety and quality, which will promote the healthy development of the market [24]. 3. **Rise of Recombinant Botulinum Toxin** - Recombinant botulinum toxin is anticipated to become a future trend due to its lower biological risks, higher purity, and production efficiency, addressing limitations of traditional products [25].

Group 1 - The core viewpoint of the article highlights the decline of the China-South Korea Free Trade Zone concept, which fell by 1.52%, ranking among the top declines in concept sectors [1] - The article provides a detailed list of concept sectors with their respective daily performance, showing that the Hair Medical sector led with a gain of 2.02%, while the China-South Korea Free Trade Zone was the worst performer [1] - The article notes that the China-South Korea Free Trade Zone concept experienced a net outflow of 119 million yuan, with major stocks like Lianyungang and Qingdao Jinkwang seeing significant capital outflows [1] Group 2 - The article lists the top stocks with net outflows in the China-South Korea Free Trade Zone concept, with Lianyungang seeing a decline of 7.36% and a net outflow of 62.06 million yuan [1] - Other notable stocks with significant net outflows include Qingdao Jinkwang and Xinhua Jin, which experienced declines of 1.17% and 1.91%, respectively [1] - Conversely, stocks like Langzi Co. and Liaogang Co. saw net inflows, indicating some investor interest despite the overall sector decline [1]

Industry Overview - The baby and children's clothing industry caters to children aged 0-14 years, with a focus on quality and safety standards in design and production [1][4] - The market size of China's baby and children's clothing industry has grown from 157.08 billion yuan in 2016 to 260.7 billion yuan in 2024, reflecting a robust growth trend [1][12] Market Environment - The demand for baby and children's clothing is directly linked to birth rates and national fertility policies, with a projected increase in birth rates to 9.54 million in 2024 [6][10] - Despite a decline in birth rates in recent years, the rising costs associated with child-rearing have led to increased spending on baby and children's clothing, with average costs reaching 538,000 yuan per child [8][10] Competitive Landscape - The market is characterized by intense competition, featuring both domestic brands like Balabala and international brands such as Disney and Nike Kids [14][15] - Major players include Jinfa Labi, Semir, and Anner, with varying market shares and brand recognition [15][18] Development Trends - The market is expected to continue expanding, driven by increasing birth rates and a shift towards higher quality and more personalized clothing options [20] - Sales channels are diversifying, with a significant shift towards online platforms, while offline channels are innovating to enhance customer experience [21] - Technological innovation and environmental considerations are becoming key drivers of industry growth, with a focus on smart and eco-friendly products [22]

Group 1 - The concept of China-South Korea Free Trade Zone has seen a rise of 2.30%, ranking second among concept sectors, with 8 stocks increasing in value, including Lianyungang which hit the daily limit, and Huaguang Yuanhai, Qingdao Jinwang, and Rizhao Port showing notable gains of 26.88%, 3.41%, and 1.87% respectively [1][2] - The main inflow of funds into the China-South Korea Free Trade Zone concept sector amounted to 147 million yuan, with Lianyungang leading the net inflow at 180 million yuan, followed by Qingdao Jinwang, Qingdao Shuangxing, and Langzi Co., which received net inflows of 68.51 million yuan, 15.67 million yuan, and 14.28 million yuan respectively [2][3] - In terms of fund inflow ratios, Lianyungang, Chunxue Food, and Liaogang Co. had the highest net inflow rates of 11.08%, 5.63%, and 3.36% respectively [3] Group 2 - The stocks with the largest declines included Xinhua Jin, Haicheng Bangda, and Haodangjia, which fell by 9.34%, 3.27%, and 0.85% respectively [1][4] - The trading volume and turnover rates for the stocks in the China-South Korea Free Trade Zone concept varied, with Lianyungang showing a turnover rate of 18.09% and Qingdao Jinwang at 35.94% [3]